Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Arthritis and Rheumatology- United Kingdom

doi 10.1002/art.40841

Full Text

Abstract

Available in

Categories

Date

May 25, 2019

Authors

Peter C. Taylor

Michael E. Weinblatt

Gerd R. Burmester

Terence P. Rooney

Claudia A. Salinas

Anabela Cardoso

Miguel A. González‐Gay

Tsutomu Takeuchi

Publisher

Wiley

Related search

Baricitinib: A New Oral Treatment for Rheumatoid Arthritis

English

Safety Profile of Baricitinib in Patients With Active Rheumatoid Arthritis With Over 2 Years Median Time in Treatment

Journal of Rheumatology

English

Evaluation of Hepatitis B Virus in Clinical Trials of Baricitinib in Rheumatoid Arthritis

English

Rheumatoid Arthritis and Cardiovascular Disease

Current Opinion in Rheumatology

English

Safety of Rituximab in Rheumatoid Arthritis

English

Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain

ClinicoEconomics and Outcomes Research

English

Mean Cost Per Number Needed to Treat of Baricitinib Versus Adalimumab in the Treatment of Rheumatoid Arthritis in Italy

Global and Regional Health Technology Assessment

English

Treatment of Rheumatoid Arthritis With ATP

Annals of the Rheumatic Diseases

Molecular Biology

English

Cardiovascular Co-Morbidity in Patients With Rheumatoid Arthritis: A Narrative Review of Risk Factors, Cardiovascular Risk Assessment and Treatment

BMC Rheumatology

English